Syrups and other preparations for making beverages;
non-alcoholic beverages fortified with niacinamide (vitamin
B3); non-alcoholic fruit juice beverages; non-alcoholic
beverages; non-alcoholic beverages fortified with vitamins;
vegetable-based beverages and fruit-based beverages; soft
drinks; non-alcoholic beverages fortified with taurine;
non-alcoholic carbonated beverages; energy drinks.
2.
PYRROLOPYRIDINE DERIVATIVES FOR CURING HIV INFECTION
The present invention relates to Compound I, or a racemate, a stereoisomer or a pharmaceutically acceptable salt thereof, which is for use in a method of curing HIV-1 infection, wherein the method comprises administering Compound I, or a racemate, a stereoisomer or a pharmaceutically acceptable salt thereof, to a subject and determining the efficacy of the curing by determining the reactivation potential of a retroviral reservoir of the subject, so as to determine whether or not treatment can be stopped.
A61K 31/437 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle condensés en ortho ou en péri avec des systèmes hétérocycliques le système hétérocyclique contenant un cycle à cinq chaînons ayant l'azote comme hétéro-atome du cycle, p. ex. indolizine, bêta-carboline
A61P 31/18 - Antiviraux pour le traitement des virus ARN du HIV
3.
METHOD FOR PREPARING 4'-THIO-5-AZA-2'-DEOXYCYTIDINE
The present invention relates to a method for preparing 4′-thio-5-aza-2′-deoxycytidine which exhibits DNMT1 inhibitory activity. The production method according to the present invention can enhance reaction efficiency through efficient process development and can stereoselectively prepare 4′-thio-5-aza-2′-deoxycytidine, and thus is economical and appropriate for mass production.
C07D 409/04 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes de soufre comme uniques hétéro-atomes du cycle contenant deux hétérocycles liés par une liaison directe de chaînon cyclique à chaînon cyclique
Syrups and other preparations for making beverages;
non-alcoholic beverages fortified with niacinamide;
non-alcoholic fruit juice beverages; non-alcoholic
beverages; non-alcoholic beverages fortified with vitamins;
vegetable-based beverages and fruit-based beverages; soft
drinks; non-alcoholic beverages fortified with taurine;
non-alcoholic carbonated beverages; energy drinks; mineral
water; non-alcoholic malt beverages.
Syrups and other preparations for making beverages;
non-alcoholic beverages fortified with niacinamide;
non-alcoholic fruit juice beverages; non-alcoholic
beverages; non-alcoholic beverages fortified with vitamins;
vegetable-based beverages and fruit-based beverages; soft
drinks; non-alcoholic beverages fortified with taurine;
non-alcoholic carbonated beverages; energy drinks; mineral
water; non-alcoholic malt beverages.
Mineral water; non-alcoholic beverages fortified with
niacinamide; non-alcoholic malt beverages; non-alcoholic
carbonated beverages; non-alcoholic fruit juice beverages;
non-alcoholic beverages; non-alcoholic beverages fortified
with vitamins; syrups and other preparations for making
beverages; energy drinks; vegetable-based beverages and
fruit-based beverages; soft drinks; non-alcoholic beverages
fortified with taurine.
Mineral water; non-alcoholic beverages fortified with
niacinamide; non-alcoholic malt beverages; non-alcoholic
carbonated beverages; non-alcoholic fruit juice beverages;
non-alcoholic beverages; non-alcoholic beverages fortified
with vitamins; syrups and other preparations for making
beverages; energy drinks; vegetable-based beverages and
fruit-based beverages; soft drinks; non-alcoholic beverages
fortified with taurine.
Mineral water; non-alcoholic beverages fortified with
niacinamide (vitamin B3); non-alcoholic malt beverages;
non-alcoholic fruit juice beverages; non-alcoholic
beverages; non-alcoholic beverages fortified with vitamins;
syrups and other preparations for making beverages;
vegetable-based beverages and fruit-based beverages; soft
drinks; non-alcoholic beverages fortified with taurine.
Advertising services relating to cosmetics; wholesale store
services featuring skin care preparations for medical
purposes; retail store services featuring skin care
preparations for medical purposes; wholesale store services
featuring medicinal creams; wholesale store services
featuring nutraceuticals for use as a dietary supplement;
wholesale store services featuring medicated soaps;
providing consumer product information relating to
cosmetics; marketing research in the fields of cosmetics,
perfumery and beauty products; wholesale store services
featuring air deodorants; wholesale store services featuring
tissues and wipes impregnated with pharmaceutical lotions
and creams; wholesale store services featuring cosmetics;
retail store services featuring cosmetics; wholesale store
services featuring functional cosmetics being skin care
preparations; wholesale store services featuring body and
beauty care cosmetics; wholesale store services featuring
cosmetic preparations for the hair and scalp; wholesale
store services featuring tissues impregnated with cosmetic
lotions; wholesale store services featuring aromatics
(perfumes) for personal use; wholesale store services
featuring cosmetic utensils; wholesale store services
featuring toiletry preparations; retail store services
featuring toiletry preparations; wholesale store services
featuring cosmetic preparations for the care of mouth and
teeth; retail and wholesale services through a comprehensive
shopping mall by internet; business intermediary services
relating to mail order by telecommunications.
Mineral water; non-alcoholic beverages fortified with
niacinamide; non-alcoholic malt beverages; non-alcoholic
carbonated beverages; non-alcoholic fruit juice beverages;
non-alcoholic beverages; non-alcoholic beverages fortified
with vitamins; syrups and other preparations for making
beverages; energy drinks; vegetable-based beverages and
fruit-based beverages; soft drinks; non-alcoholic beverages
fortified with taurine.
Non-alcoholic fruit juice beverages; non-alcoholic
beverages; non-alcoholic beverages fortified with vitamins;
vegetable-based beverages and fruit-based beverages; soft
drinks; non-alcoholic beverages fortified with taurine.
The present invention relates to a nucleic acid molecule for preventing or treating viral infection or cancer, comprising a nucleic acid encoding a signal peptide and a nucleic acid encoding an antigen. Furthermore, it relates to a vaccine composition for preventing or treating viral infection or cancer, comprising the nucleic acid molecule.
The present invention relates to a nucleic acid molecule for preventing or treating viral infection or cancer, comprising a nucleic acid encoding a signal peptide and a nucleic acid encoding an antigen. Furthermore, it relates to a vaccine composition for preventing or treating viral infection or cancer, comprising the nucleic acid molecule.
The nucleic acid molecule according to the present invention has excellent intracellular protein expression rate and protein secretion ability to the outside of the cell. In addition, when administered in vivo, it allows the subject to acquire humoral immunity, such as inducing antigen-specific neutralizing antibodies, and cellular immunity, such as increasing the amount of immune cells directly involved in killing the virus. Thus, it can be useful as a vaccine for the prevention and treatment of viral infection or cancer.
The present invention relates to an improved method for oligonucleotide synthesis. In the method for oligonucleotide synthesis according to the present invention, a synthesis cycle is performed at a temperature lower than room temperature, thereby suppressing side reactions occurring during the synthesis process and stably synthesizing oligonucleotides with higher purity.
C07H 21/00 - Composés contenant au moins deux unités mononucléotide comportant chacune des groupes phosphate ou polyphosphate distincts liés aux radicaux saccharide des groupes nucléoside, p. ex. acides nucléiques
C07H 1/00 - Procédés de préparation des dérivés du sucre
C12N 15/113 - Acides nucléiques non codants modulant l'expression des gènes, p. ex. oligonucléotides anti-sens
The present invention relates to a pyrrolopyridine compound and a use thereof, the compound having antiviral activity, particularly, a compound of chemical formula 1 having high selectivity and physiological activity against human immunodeficiency virus (HIV), or a pharmaceutically acceptable salt, stereoisomer, hydrate, solvate, tautomer or prodrug thereof. [Chemical formula 1]
A61K 31/437 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle condensés en ortho ou en péri avec des systèmes hétérocycliques le système hétérocyclique contenant un cycle à cinq chaînons ayant l'azote comme hétéro-atome du cycle, p. ex. indolizine, bêta-carboline
A61P 31/18 - Antiviraux pour le traitement des virus ARN du HIV
The present invention relates to: a heteroaryl compound having antiviral activity, in particular, a compound of chemical formula 1, having high selectivity and physiological activity against human immunodeficiency virus (HIV), or a pharmaceutically acceptable salt, a stereoisomer, a hydrate, a solvate, a tautomer, or a prodrug thereof; and a use thereof. [Chemical formula 1]
A61K 31/444 - Pyridines non condenséesLeurs dérivés hydrogénés contenant d'autres systèmes hétérocycliques contenant un cycle à six chaînons avec l'azote comme hétéro-atome du cycle, p. ex. amrinone
A61P 31/18 - Antiviraux pour le traitement des virus ARN du HIV
16.
CONTROLLED-RELEASE FORMULATION COMPRISING CAFFEINE, AND PREPARATION METHOD THEREFOR
DONG-A PHARMACEUTICAL CO., LTD. (République de Corée)
Inventeur(s)
Jang, Bong Seok
Kim, Sungrae
Park, Juhwan
Lee, Hyo Jung
Park, Junwoo
Sung, Si Woo
Kim, Hee Eun
Yun, Chun Hee
Abrégé
The present invention relates to an orally administered formulation comprising caffeine as an active ingredient and having a drug-release controlling property, and a method for preparing same by using 3D printing and relates to a pharmaceutical composition and a food composition, of the formulation, for preventing or treating jet lag, and a composition to be applied to a 3D printer.
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A61K 47/32 - Composés macromoléculaires obtenus par des réactions faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. carbomères
DONG-A PHARMACEUTICAL CO., LTD. (République de Corée)
Inventeur(s)
Jun, Yunju
Han, Youngsun
Park, Hyounggeun
Cho, Youngwoong
Han, Hyewon
Abrégé
The present invention relates to: a composition for a gummy jelly, the composition including sugar alcohols, oligosaccharides, and a gelling agent; a gummy jelly prepared by using same; and a preparation method thereof.
DONG-A PHARMACEUTICAL CO., LTD. (République de Corée)
Inventeur(s)
Jang, Bong Seok
Kim, Sungrae
Park, Juhwan
Lee, Hyo Jung
Park, Junwoo
Sung, Si Woo
Kim, Hee Eun
Yun, Chun Hee
Abrégé
The present invention relates to an orally administered formulation comprising melatonin as an active ingredient and having a drug-release controlling property, and a method for preparing same by using 3D printing and relates to a pharmaceutical composition and a food composition, of the formulation, for preventing or treating jet lag, and a composition to be applied to a 3D printer.
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A61K 47/36 - PolysaccharidesLeurs dérivés, p. ex. gommes, amidon, alginate, dextrine, acide hyaluronique, chitosane, inuline, agar-agar ou pectine
A61K 47/10 - AlcoolsPhénolsLeurs sels, p. ex. glycérolPolyéthylène glycols [PEG]PoloxamèresAlkyléthers de PEG/POE
A61K 47/34 - Composés macromoléculaires obtenus par des réactions autres que celles faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. polyesters, acides polyaminés, polysiloxanes, polyphosphazines, copolymères de polyalkylène glycol ou de poloxamères
A61K 47/14 - Esters d’acides carboxyliques, p. ex. acides gras monoglycérides, triglycérides à chaine moyenne, parabènes ou esters d’acide gras de PEG
A61K 31/4045 - Indole-alkylaminesLeurs amides, p. ex. sérotonine, mélatonine
A61P 25/00 - Médicaments pour le traitement des troubles du système nerveux
A61P 43/00 - Médicaments pour des utilisations spécifiques, non prévus dans les groupes
A23L 33/10 - Modification de la qualité nutritive des alimentsProduits diététiquesLeur préparation ou leur traitement en utilisant des additifs
The present invention relates to a polymorphism of a triazolopyrimidinone derivative exhibiting tankyrase inhibitory activity, and a preparation method therefor. The novel polymorphism of the present invention exhibits excellent non-hygroscopicity and stability, and exhibits excellent solubility and bioavailability, and thus is suitable as a raw material for pharmaceutical preparations.
FOOD COMPOSITION FOR HANGOVER RELIEF COMPRISING MIXED FERMENTED PRODUCT OF RICE BRAN AND CABBAGE AND HOVENIA DULCIS FRUIT EXTRACT AS ACTIVE INGREDIENT, AND METHOD FOR MANUFACTURING SAME
DONG-A PHARMACEUTICAL CO., LTD. (République de Corée)
Inventeur(s)
Han, Gi Dong
Lee, Tae Ho
Park, Hyoung Geun
Cho, Sung Mo
Abrégé
The present invention relates to a food composition for hangover relief, the food composition comprising a mixed fermented product of rice bran and cabbage and a Hovenia dulcis fruit extract as active ingredients. A mixture obtained by mixing the mixed fermented product of rice bran and cabbage and the Hovenia dulcis fruit extract in a specific weight ratio was determined to exhibit excellent alcohol dehydrogenase (ADH) and acetaldehyde dehydrogenase (ALDH) activity promotion effects and can thus be effectively used as a composition for preventing, treating, or alleviating alcoholic liver diseases.
A23L 33/105 - Extraits de plantes, leurs doublons artificiels ou leurs dérivés
A23L 29/00 - Aliments ou produits alimentaires contenant des additifsLeur préparation ou leur traitement
A61K 36/899 - Poaceae ou Gramineae (famille des céréales), p. ex. bambou, blé ou canne à sucre
A61K 36/31 - Brassicaceae ou Cruciferae (famille de la moutarde), p. ex. broccoli, chou ou chou-rave
A61P 1/16 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif des troubles de la vésicule biliaire ou du foie, p. ex. protecteurs hépatiques, cholagogues, cholélitholytiques
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Dietary supplements containing garcinia as the primary
ingredient; nutritional supplements containing grains as the
primary ingredient; dietary supplements in the form of
capsules for body weight control; protein supplements;
mineral preparations; dietetic supplements with a cosmetic
effect; meal replacement powders; dietary supplemental
drinks; dietary supplements; nutraceuticals for use as
dietary supplements; dietary fiber; dietary supplements used
for weight loss; dietary supplements containing collagen as
the primary ingredient; nutritional supplements containing
collagen as the primary ingredient.
The present invention relates to a novel oligonucleotide primer used for the synthesis of 5'-capped RNA. The novel oligonucleotide primer for RNA capping, represented by chemical formula 1 in the present invention, can be usefully utilized in the fields of nucleic acid therapeutic agents or vaccines.
C07H 21/02 - Composés contenant au moins deux unités mononucléotide comportant chacune des groupes phosphate ou polyphosphate distincts liés aux radicaux saccharide des groupes nucléoside, p. ex. acides nucléiques avec le ribosyle comme radical saccharide
C12N 15/113 - Acides nucléiques non codants modulant l'expression des gènes, p. ex. oligonucléotides anti-sens
C12P 19/34 - Polynucléotides, p. ex. acides nucléiques, oligoribonucléotides
A61K 31/7105 - Acides ribonucléiques naturels, c.-à-d. contenant uniquement des riboses liés à l'adénine, la guanine, la cytosine ou l'uracile et ayant des liaisons 3'-5' phosphodiester
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
The present invention relates to a method for preparing a triazolopyrimidinone derivative exhibiting tankyrase inhibitory activity and an intermediate thereof. The preparation method of the present invention can improve reaction efficiency through the development of efficient processes and can prepare a triazolopyrimidinone derivative compound with high purity and high yield, and thus is economical and suitable for mass production.
03 - Produits cosmétiques et préparations de toilette; préparations pour blanchir, nettoyer, polir et abraser.
Produits et services
Cosmetic preparations for the care of mouth and teeth;
breath freshening sprays; non-medicated mouthwashes and
gargles; non-medicated dental rinses; non-medicated
dentifrices; toiletry preparations; preparations for
cleaning dentures; tooth cleaning preparations; dentifrices;
cosmetics.
The present invention relates to a method for preparing a pyrrolopyridine derivative compound exhibiting antiviral activity, and a novel intermediate used therein. The preparation method of the present invention enables reaction steps to be reduced through effective process development and a high purity pyrrolopyridine derivative compound to be prepared in a high yield, and thus enables production costs to be remarkably reduced so as to be economical and to be suitable for mass production.
The present invention relates to a solid dispersion of a triazolopyrimidinone derivative exhibiting tankyrase inhibitory activity, and a method for preparing same. The solid dispersion of the triazolopyrimidinone derivative represented by chemical formula (I) according to the present invention has high solubility and excellent bioavailability and can thus be effectively used as a pharmaceutical ingredient.
The present invention relates to a pharmaceutical composition for the prevention or treatment of KRAS G12 mutant cancer, comprising a triazolopyrimidinone derivative and an MEK inhibitor. The composition according to the present invention exhibits a significant synergistic effect on anticancer activity against KRAS G12 mutant cancer and inhibition of tumor formation, and thus may be useful as a therapeutic regimen or complex for KRAS G12 mutant cancer.
The present invention relates to a combination therapy of a triazolopyrimidinone derivative and an MEK inhibitor, the combination therapy according to the invention exhibiting a significant synergistic effect with respect to anticancer activity and inhibition of tumor formation compared to the administration of each active ingredient alone, and may be utilized as a therapeutic regimen or complex for cancer.
(1) Wholesale store services featuring air deodorants; wholesale store services featuring cosmetic preparations for the care of mouth and teeth; wholesale store services featuring multi-functional skin care preparations; wholesale store services featuring cosmetic preparations for the hair and scalp; wholesale store services featuring body and beauty care cosmetics; wholesale store services featuring toiletry preparations; retail store services featuring toiletry preparations; wholesale store services featuring nutraceuticals for use as a dietary supplement; wholesale store services featuring medicated soaps; wholesale store services featuring tissues and wipes impregnated with pharmaceutical lotions and creams; retail store services featuring skin care preparations for medical purposes; wholesale store services featuring skin care preparations for medical purposes; wholesale store services featuring medicinal creams; wholesale store services featuring fragrance for the human body; comprehensive shopping mall by internet; business intermediary services relating to mail order by telecommunications; wholesale store services featuring tissues impregnated with cosmetic lotions; wholesale store services featuring cosmetic utensils; advertising services relating to cosmetics; providing consumer product information relating to cosmetics; wholesale store services featuring cosmetics; retail store services featuring cosmetics; marketing
03 - Produits cosmétiques et préparations de toilette; préparations pour blanchir, nettoyer, polir et abraser.
Produits et services
(1) Non-medicated toiletry preparations; cuticle removing preparations; functional cosmetics being skin care preparations; skin milk for men; anti-aging cosmetic preparations; make-up; cosmetic preparations for the hair and scalp; body and beauty care cosmetics; beauty care cosmetics; non-medicated preparations for the care of skin, hair and scalp; sun block [cosmetics]; skin whitening preparations; cosmetics; essential oils for use in the manufacture of scented products; exfoliant tissues; soaps for household use; multi-functional shampoo; breath freshening preparations for personal hygiene; shampoo for animals (care preparations other than for medical or veterinary use)
31.
COMPOSITION FOR FILM COATING, AND FILM COATING LIQUID COMPRISING SAME
DONG-A PHARMACEUTICAL CO., LTD. (République de Corée)
Inventeur(s)
Kim, Soyeon
Park, Junwoo
Kim, Sungrae
Abrégé
The present invention relates to a film coating composition, and specifically to: a film coating composition having excellent safety and shielding properties; and a film coating liquid comprising same.
A23P 20/10 - Revêtement avec des produits de revêtement comestibles, p. ex. avec des huiles ou des graisses
A61K 9/28 - DragéesPilules ou comprimés avec revêtements
A23P 20/18 - Appareils ou procédés de revêtement avec des produits liquides ou semi-liquides par revêtement par pulvérisation, par revêtement par lit fluidisé ou par coulée
The present invention pertains to: a polymorph of a pyrrolopyridine derivative which is a non-catalytic site integrase inhibitor; and a method for producing same. The novel polymorph of the present invention exhibits excellent non-hygroscopicity and stability and is thus suitable for pharmaceutical preparations.
A61K 31/437 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle condensés en ortho ou en péri avec des systèmes hétérocycliques le système hétérocyclique contenant un cycle à cinq chaînons ayant l'azote comme hétéro-atome du cycle, p. ex. indolizine, bêta-carboline
A61P 31/18 - Antiviraux pour le traitement des virus ARN du HIV
33.
NOVEL IONIZABLE LIPID AND LIPID NANOPARTICLE CONTAINING SAME
The present invention relates to a novel ionizable lipid containing a biodegradable bond. Specifically, the ionizable lipid containing a biodegradable ester and/or amide bond according to the present invention stably delivers an anionic drug when prepared into lipid nanoparticles, and exhibits an excellent effect, in particular, in delivering nucleic acids, and thus can be effectively used in related technical fields such as lipid nanoparticle-mediated gene therapy.
C07C 271/20 - Esters des acides carbamiques ayant des atomes d'oxygène de groupes carbamate liés à des atomes de carbone acycliques avec les atomes d'azote des groupes carbamate liés à des atomes d'hydrogène ou à des atomes de carbone acycliques à des atomes de carbone de radicaux hydrocarbonés substitués par des atomes d'azote ne faisant pas partie de groupes nitro ou nitroso
C07C 229/26 - Composés contenant des groupes amino et carboxyle liés au même squelette carboné ayant des groupes amino et carboxyle liés à des atomes de carbone acycliques du même squelette carboné le squelette carboné étant acyclique et saturé ayant plus d'un groupe amino lié au squelette carboné, p. ex. lysine
C07C 237/08 - Amides d'acides carboxyliques, le squelette carboné de la partie acide étant substitué de plus par des groupes amino ayant les atomes de carbone des groupes carboxamide liés à des atomes de carbone acycliques du squelette carboné le squelette carboné étant acyclique et saturé ayant l'atome d'azote d'au moins un des groupes carboxamide lié à un atome de carbone acyclique d'un radical hydrocarboné substitué par des atomes d'oxygène liés par des liaisons simples
A61K 9/127 - Vecteurs à bicouches synthétiques, p. ex. liposomes ou liposomes comportant du cholestérol en tant qu’unique agent tensioactif non phosphatidylique
The present invention relates to a novel ionizable lipid containing a biodegradable bond for in vivo drug delivery. Specifically, the ionizable lipid containing a biodegradable ester or amide bond, of the present invention, stably delivers an anionic drug when prepared into lipid nanoparticles, and exhibits an excellent effect, in particular, during nucleic acid delivery, and thus can be effectively used in related technical fields such as that of lipid nanoparticle-mediated gene therapy.
C07D 211/26 - Composés hétérocycliques contenant des cycles pyridiques hydrogénés, non condensés avec d'autres cycles avec uniquement des atomes d'hydrogène et de carbone liés directement à l'atome d'azote du cycle ne comportant pas de liaison double entre chaînons cycliques ou entre chaînons cycliques et chaînons non cycliques avec des radicaux hydrocarbonés ou des radicaux hydrocarbonés substitués, liés directement aux atomes de carbone du cycle avec des radicaux hydrocarbonés substitués liés aux atomes de carbone du cycle avec des radicaux hydrocarbonés, substitués par des atomes d'azote
A61K 9/127 - Vecteurs à bicouches synthétiques, p. ex. liposomes ou liposomes comportant du cholestérol en tant qu’unique agent tensioactif non phosphatidylique
A61K 47/22 - Composés hétérocycliques, p. ex. acide ascorbique, tocophérol ou pyrrolidones
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
03 - Produits cosmétiques et préparations de toilette; préparations pour blanchir, nettoyer, polir et abraser.
Produits et services
Non-medicated soaps for household use; exfoliant tissues pre-moistened with cosmetic preparations; cuticle removing preparations; breath freshening preparations for personal hygiene; functional cosmetics being skin care preparations; cosmetic creams for skin care; cosmetic skin milk for men; anti-aging cosmetic preparations; non-medicated grooming preparations in the nature of shampoos for animals; make-up; cosmetic preparations for the hair and scalp; body and beauty care cosmetics; beauty care cosmetics; non-medicated toiletry preparations; non-medicated preparations for the care of skin, hair and scalp; shampoos; sun block cosmetics; skin whitening preparations; essential oils for use in the manufacture of scented products; cosmetics; all of the aforementioned goods containing a cosmetic-grade heparin-based ingredient
03 - Produits cosmétiques et préparations de toilette; préparations pour blanchir, nettoyer, polir et abraser.
Produits et services
Cosmetic preparations for the care of mouth and teeth; breath freshening sprays; non-medicated mouthwashes and gargles; non-medicated dental rinses; non-medicated dentifrices; non-medicated toiletry preparations; preparations for cleaning dentures; tooth cleaning preparations; dentifrices; cosmetics
03 - Produits cosmétiques et préparations de toilette; préparations pour blanchir, nettoyer, polir et abraser.
Produits et services
Soaps for household use; exfoliant tissues; cuticle removing
preparations; breath freshening preparations for personal
hygiene; functional cosmetics being skin care preparations;
multi functional shampoo; skin milk for men; anti-aging
cosmetic preparations; shampoo for animals (care
preparations other than for medical or veterinary use);
make-up; cosmetic preparations for the hair and scalp; body
and beauty care cosmetics; beauty care cosmetics;
non-medicated toiletries; non-medicated preparations for the
care of skin, hair and scalp; sun block cosmetics; skin
whitening preparations; essential oils for use in the
manufacture of scented products; cosmetics.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Pharmaceutical preparations for activating cellular
function; ointments for pharmaceutical purposes;
pharmaceutical agents for epidermis; pharmaceutical
preparation for skin care; pharmaceutical preparations for
treating skin disorders; preparations for the treatment of
burns.
39.
COMPOSITION COMPRISING PH-SENSITIVE LIPID NANOPARTICLES CONTAINING CATIONIC MATERIAL
DONG-A PHARMACEUTICAL CO., LTD. (République de Corée)
Inventeur(s)
Han, Sangduk
Kang, Min-Kyung
Hyun, Seungmin
Lee, Sungwon
Park, Hyoyoung
Abrégé
The present invention relates to pH-sensitive nanoparticles comprising cationic materials and to a composition comprising same, wherein the nanoparticles can stably encapsulate a high content of active substances and are remarkably improved in terms of the skin retention and delivery effects of active ingredients when applied to the skin.
A61K 47/20 - Composés organiques, p. ex. hydrocarbures naturels ou synthétiques, polyoléfines, huile minérale, gelée de pétrole ou ozocérite contenant du soufre, p. ex. sulfoxyde de diméthyle [DMSO], docusate, laurylsulfate de sodium ou acides aminosulfoniques
A61K 47/24 - Composés organiques, p. ex. hydrocarbures naturels ou synthétiques, polyoléfines, huile minérale, gelée de pétrole ou ozocérite contenant des atomes autres que des atomes de carbone, d'hydrogène, d'oxygène, d'halogènes, d'azote ou de soufre, p. ex. cyclométhicone ou phospholipides
A61P 17/00 - Médicaments pour le traitement des troubles dermatologiques
A61K 8/02 - Cosmétiques ou préparations similaires pour la toilette caractérisés par une forme physique particulière
A61K 8/46 - Cosmétiques ou préparations similaires pour la toilette caractérisés par la composition contenant des composés organiques contenant du soufre
A61K 8/58 - Cosmétiques ou préparations similaires pour la toilette caractérisés par la composition contenant des composés organiques contenant des atomes autres que des atomes de carbone, hydrogène, halogène, oxygène, azote, soufre ou phosphore
A61Q 19/08 - Préparations contre le vieillissement
A61Q 19/00 - Préparations pour les soins de la peau
The present invention relates to a composition for transpulmonary delivery of drugs and a use thereof. Lipid nanoparticles containing ionizable lipids and cationic lipids of the present invention are specifically delivered to lung tissue and specific cells thereof, have excellent biocompatibility, and can deliver anionic drugs with high efficiency, and thus can be useful in relevant technical fields such as lipid nanoparticle-mediated gene therapy.
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
A61K 31/7088 - Composés ayant au moins trois nucléosides ou nucléotides
A61P 11/00 - Médicaments pour le traitement des troubles du système respiratoire
42.
MICROFLUIDIC MIXING STRUCTURE AND MICROFLUIDIC MIXING APPARATUS COMPRISING SAME
POSTECH RESEARCH AND BUSINESS DEVELOPMENT FOUNDATION (République de Corée)
ST PHARM CO., LTD. (République de Corée)
Inventeur(s)
Kang, Byung Kwon
Na, Gi Su
Kim, Dong Pyo
Kim, Kyungjin
Yang, Joosung
Choi, Kang Hyun
Kim, Uk-Il
Lee, Joo Young
Abrégé
Disclosed are a microfluidic mixing structure and a microfluidic mixing apparatus comprising same. The microfluidic mixing structure according to an aspect of the present invention is for mixing a first fluid and a second fluid while moving them in a first direction and comprises: a first mixing unit including a first body which has an inlet through which the first fluid and the second fluid are introduced, and a first space in which the first fluid and the second fluid are mixed; and a second mixing unit which is provided on the rear side of the first mixing unit when viewed in the first direction, and includes a second body having a second space through which a mixed fluid obtained in the first mixing unit flows, wherein the first space in the first mixing unit and the second space in the second mixing unit are provided on opposite sides of an imaginary line extending in the first direction, the flow direction of the mixed fluid, in which the mixed fluid is introduced from an outlet of the first mixing unit into an inlet of the second mixing unit, is opposite to the first direction, and the first mixing unit and the second mixing unit include curved surfaces that are bilaterally symmetric with respect to the center in the width direction when viewed in the first direction.
30 - Aliments de base, thé, café, pâtisseries et confiseries
Produits et services
(1) Fruit jelly candy; sugar confectionery; candy; flavored jelly crystals for making jelly confectionery; confectionery fruit jellies; confectionery fruit jellies enhanced with collagen; confectionery fruit jellies enhanced with taurine.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Nutraceutical preparations consisting primarily of collagen, namely, nutraceuticals for use as a dietary supplement consisting primarily of collagen; dietary supplements consisting primarily of collagen; slimming pills; nutraceutical preparations consisting primarily of garcinia, namely, nutraceuticals for use as a dietary supplement consisting primarily of garcinia; meal replacement powders, namely, meal replacement drink mixes adapted for medical use; dietary supplements with cosmetic effects; dietary supplemental drinks; dietary supplements; nutraceuticals for use as dietary supplements; protein dietary supplements; dietary fiber to aid digestion; diet capsules; nutraceutical preparations consisting primarily of grains, namely, nutraceuticals for use as a dietary supplement consisting primarily of grains; mineral preparations for medical purposes; nutraceuticals for use as a dietary supplement containing angelic root; nutraceuticals for use as a dietary supplement containing cnidium; nutraceuticals for use as a dietary supplement containing safflower leaves; nutraceuticals for use as a dietary supplement containing seaweed
The present invention relates to a platform for preparing a nucleic acid vaccine and, specifically, to a nucleic acid molecule comprising a polynucleotide encoding a signal peptide, a polynucleotide encoding a Th cell epitope, a polynucleotide encoding a membrane protein and/or a polynucleotide encoding an antigenic protein. In addition, the present invention relates to a vaccine composition for preventing or treating viral infections, containing the nucleic acid molecule. The platform for preparing an mRNA vaccine, according to the present invention, enables rapid preparation of an mRNA vaccine for a new mutant virus. In addition, a nucleic acid molecule prepared by the platform has excellent intracellular antigen protein expression and extracellular secretion of an antigen protein, and allows an individual to acquire immunity to a virus, and thus can be effectively used for preventing and treating viral infections.
The present invention relates to a method for preparing 4'-thio-5-aza-2'-deoxycytidine which exhibits DNMT1 inhibitory activity. The production method according to the present invention can enhance reaction efficiency through efficient process development and can stereoselectively prepare 4'-thio-5-aza-2'-deoxycytidine, and thus is economical and appropriate for mass production.
A61K 31/706 - Composés ayant des radicaux saccharide et des hétérocycles ayant l'azote comme hétéro-atome d'un cycle, p. ex. nucléosides, nucléotides contenant des cycles à six chaînons avec l'azote comme hétéro-atome d'un cycle
C07F 7/18 - Composés comportant une ou plusieurs liaisons C—Si ainsi qu'une ou plusieurs liaisons C—O—Si
The present invention relates to a novel oligonucleotide primer used for the synthesis of 5′-capped RNA. The novel oligonucleotide primer for RNA capping provided as Formula 1 in the present invention can be usefully utilized in the fields of nucleic acid therapeutic agents or vaccines.
C07H 21/02 - Composés contenant au moins deux unités mononucléotide comportant chacune des groupes phosphate ou polyphosphate distincts liés aux radicaux saccharide des groupes nucléoside, p. ex. acides nucléiques avec le ribosyle comme radical saccharide
C12N 15/67 - Méthodes générales pour favoriser l'expression
The present invention relates to a pyrrolopyridine derivative, a racemate thereof, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, and use thereof. The compound of the present invention has high selectivity and bioactivity against human immunodeficiency virus (HIV), and low toxicity, thus being useful as a therapeutic agent for viral infection, particularly human immunodeficiency virus (HIV) infection.
Beverages containing taurine, namely, sports drinks, energy drinks and drinking water enhanced with taurine; beverages containing vitamins, namely, sports drinks, energy drinks and drinking water enhanced with vitamins; non-alcoholic fruit juice drinks; non-alcoholic beverages, namely, energy drinks; vegetable-based beverages and fruit-based beverages; soft drinks
Beverages containing taurine, namely, sports drinks, energy drinks and drinking water enhanced with taurine; beverages containing vitamins, namely, sports drinks, energy drinks and drinking water enhanced with vitamins; non-alcoholic fruit juice drinks; non-alcoholic beverages, namely, energy drinks; vegetable-based beverages and fruit-based beverages; soft drinks
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Medicated transdermal patches for treating acne and skin blemishes; Medicated transdermal patches for use in the treatment of acne and skin blemishes; Transdermal hydrocolloid patches for use in the treatment of acne and skin blemishes
55.
IONIZABLE LIPID CONTAINING BIODEGRADABLE ESTER BOND AND LIPID NANOPARTICLES COMPRISING SAME
The present invention relates to a novel ionizable lipid containing a biodegradable ester bond. The ionizable lipid containing an ester bond, according to the present invention, stably delivers an anionic drug when prepared into lipid nanoparticles, and exhibits an excellent effect, in particular, in delivering nucleic acids, and thus can be effectively used in related technical fields such as lipid nanoparticle-mediated gene therapy.
C07D 295/04 - Composés hétérocycliques contenant des cycles polyméthylène imine d'au moins cinq chaînons, des cycles aza-3 bicyclo [3.2.2] nonane, piperazine, morpholine ou thiomorpholine, ne comportant que des atomes d'hydrogène liés directement aux atomes de carbone du cycle avec des radicaux hydrocarbonés substitués liés aux atomes d'azote du cycle
C07C 219/20 - Composés contenant des groupes amino et hydroxy estérifiés liés au même squelette carboné ayant des groupes hydroxy estérifiés et des groupes amino liés à des atomes de carbone acycliques du même squelette carboné le squelette carboné étant non saturé
A61K 47/18 - AminesAmidesUréesComposés d’ammonium quaternaireAcides aminésOligopeptides ayant jusqu’à cinq acides aminés
A61K 47/22 - Composés hétérocycliques, p. ex. acide ascorbique, tocophérol ou pyrrolidones
A61K 9/127 - Vecteurs à bicouches synthétiques, p. ex. liposomes ou liposomes comportant du cholestérol en tant qu’unique agent tensioactif non phosphatidylique
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Medicated transdermal patches for treating acne and skin blemishes; Medicated transdermal patches for use in the treatment of acne and skin blemishes; Transdermal hydrocolloid patches for use in the treatment of acne and skin blemishes
03 - Produits cosmétiques et préparations de toilette; préparations pour blanchir, nettoyer, polir et abraser.
Produits et services
Gel eye masks; cosmetic facial masks in the form of gel; functional cosmetics, namely, skin care preparations; cosmetic mask packs for use on the neck; massage gels other than for medical purposes; gel eye patches for cosmetic purposes; pores tightening mask packs used as cosmetics; cosmetic patches containing sunscreen and sun block for use on the skin; body and beauty care cosmetics; non-medicated toiletry preparations; essential oils; cosmetics for personal use; cosmetic facial packs; skin moisturizer masks; beauty masks; mask pack for cosmetic purposes; skin masks for cosmetic use; cosmetic facial masks; cosmetics; massage lotions for cosmetic purposes; cosmetic patches containing non-medicated skin care preparations for use on the skin; cosmetic patches containing non-medicated skin care preparations
58.
IONIZABLE LIPID CONTAINING BIODEGRADABLE DISULFIDE BOND AND LIPID NANOPARTICLES COMPRISING SAME
The present invention relates to a novel ionizable lipid containing a biodegradable disulfide bond. The ionizable lipid containing a disulfide bond, according to the present invention, stably delivers an anionic drug when prepared into lipid nanoparticles and exhibits an excellent effect, in particular, in delivering nucleic acids, and thus can be effectively used in related technical fields such as lipid nanoparticle-mediated gene therapy.
C07C 323/25 - Thiols, sulfures, hydropolysulfures ou polysulfures substitués par des halogènes, des atomes d'oxygène ou d'azote ou par des atomes de soufre ne faisant pas partie de groupes thio contenant des groupes thio et des atomes d'azote, ne faisant pas partie de groupes nitro ou nitroso, liés au même squelette carboné ayant les atomes de soufre des groupes thio liés à des atomes de carbone acycliques du squelette carboné le squelette carboné étant acyclique et saturé
C07C 319/22 - Préparation de thiols, de sulfures, d'hydropolysulfures ou de polysulfures d'hydropolysulfures ou de polysulfures
C07D 295/04 - Composés hétérocycliques contenant des cycles polyméthylène imine d'au moins cinq chaînons, des cycles aza-3 bicyclo [3.2.2] nonane, piperazine, morpholine ou thiomorpholine, ne comportant que des atomes d'hydrogène liés directement aux atomes de carbone du cycle avec des radicaux hydrocarbonés substitués liés aux atomes d'azote du cycle
A61K 47/20 - Composés organiques, p. ex. hydrocarbures naturels ou synthétiques, polyoléfines, huile minérale, gelée de pétrole ou ozocérite contenant du soufre, p. ex. sulfoxyde de diméthyle [DMSO], docusate, laurylsulfate de sodium ou acides aminosulfoniques
A61K 47/22 - Composés hétérocycliques, p. ex. acide ascorbique, tocophérol ou pyrrolidones
A61K 9/127 - Vecteurs à bicouches synthétiques, p. ex. liposomes ou liposomes comportant du cholestérol en tant qu’unique agent tensioactif non phosphatidylique
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
59.
METHOD FOR PREPARING TRIAZOLOPYRIMIDINONE DERIVATIVE
The present invention relates to a method for preparing a triazolopyrimidinone derivative exhibiting tankyrase inhibitory activity and an intermediate thereof. The preparation method of the present invention can improve reaction efficiency through the development of efficient processes and can prepare a triazolopyrimidinone derivative compound with high purity and high yield, and thus is economical and suitable for mass production.
DONG-A PHARMACEUTICAL CO., LTD. (République de Corée)
Inventeur(s)
Han, Sang Duk
Han, Young Sun
Park, Min Ju
Jo, Hyun Il
Lee, Eun Seok
Abrégé
The present invention relates to a bifidobacterium bifidum EPS DA-LAIM strain (KCTC 14638BP) for intestinal health, having the effect of promoting growth of lactobacillus, polysaccharides produced from same, and a composition comprising same, for ameliorating diseases caused by the excessive accumulation of active oxygen.
A23L 33/135 - Bactéries ou leurs dérivés, p. ex. probiotiques
A61K 8/99 - Cosmétiques ou préparations similaires pour la toilette caractérisés par la composition contenant des produits de constitution indéterminée ou leurs dérivés à base de micro-organismes autres que des algues ou des champignons, p. ex. à base de protozoaires ou de bactéries
A01N 63/20 - BactériesSubstances produites par des bactéries ou obtenues à partir de celles-ci
A61K 35/742 - Bactéries sporulées, p. ex. Bacillus coagulans, Bacillus subtilis, clostridium ou Lactobacillus sporogenes
A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
A23L 33/135 - Bactéries ou leurs dérivés, p. ex. probiotiques
A61K 8/99 - Cosmétiques ou préparations similaires pour la toilette caractérisés par la composition contenant des produits de constitution indéterminée ou leurs dérivés à base de micro-organismes autres que des algues ou des champignons, p. ex. à base de protozoaires ou de bactéries
A61Q 19/00 - Préparations pour les soins de la peau
DONG-A PHARMACEUTICAL CO., LTD. (République de Corée)
Inventeur(s)
Han, Sangduk
Jiang, Haihua
Hyun, Seungmin
Abrégé
The present invention relates to a cosmetic composition and a pharmaceutical composition, which comprise, as an active ingredient, Recoflavone or a salt thereof, and thus have an antioxidant effect and the excellent effects of skin whitening, elasticity, wrinkle reduction, moisturizing, anti-inflammation or the like, particularly, excellent skin-related effects.
A61K 8/49 - Cosmétiques ou préparations similaires pour la toilette caractérisés par la composition contenant des composés organiques contenant des composés hétérocycliques
A61Q 19/00 - Préparations pour les soins de la peau
A61Q 19/08 - Préparations contre le vieillissement
A61K 31/352 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p. ex. fungichromine ayant des cycles à six chaînons avec un oxygène comme seul hétéro-atome d'un cycle condensés avec des carbocycles, p. ex. cannabinols, méthanthéline
A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
A61P 17/00 - Médicaments pour le traitement des troubles dermatologiques
UNIVERSITY-INDUSTRY COOPERATION GROUP OF KYUNG HEE UNIVERSITY (République de Corée)
Inventeur(s)
Kim, Hak Won
Lee, Tae Hoon
Moon, Hye Jin
Kim, Jung Woog
Yoon, Do Won
Kim, Kyung Jin
Ahn, Seohyun
Kim, Uk-Il
Bang, Hyung Tae
Choi, Seong Mi
Lee, Seul Ki
Han, Si Yeon
Abrégé
The present invention relates to a compound having therapeutic activity for total inflammatory bowel diseases such as Crohn's disease and ulcerative colitis. An ergostenol or cholestenol derivative compound according to the present invention exhibits excellent anti-inflammatory and colitis amelioration effects, and thus has an excellent therapeutic effect on inflammatory bowel diseases.
C07J 9/00 - Stéroïdes normaux contenant du carbone, de l'hydrogène, un halogène ou de l'oxygène, substitués en position 17bèta par une chaîne de plus de deux atomes de carbone, p. ex. cholane, cholestane, coprostane
A61K 31/575 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrèneLeurs dérivés, p. ex. stéroïdes substitués en position 17 bêta par une chaîne d'au moins trois atomes de carbone, p. ex. cholane, cholestane, ergostérol, sitostérol
A61K 31/58 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrèneLeurs dérivés, p. ex. stéroïdes contenant des hétérocycles, p. ex. danazol, stanozolol, pancuronium ou digitogénine
A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
A61P 1/00 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif
The present invention relates to a nucleic acid molecule, including a nucleic acid encoding a signal peptide and a nucleic acid encoding an antigen, for prevention or treatment of viral infection or cancer. In addition, the present invention relates to a vaccine composition containing the nucleic acid molecule for prevention or treatment of viral infection or cancer. The nucleic acid molecule according to the present invention is superb in terms of intracellular protein expression rate and extracellular protein secretion. In addition, when administered in vivo, the nucleic acid molecule allows the subject to acquire the humoral immunity of inducing antigen-specific neutralizing antibodies and the cellular immunity of increasing an amount of immune cells directly involved in killing viruses and as such, can be advantageously utilized as a vaccine for prevention and treatment of virus infection or cancer.
C12N 15/62 - Séquences d'ADN codant pour des protéines de fusion
C07K 14/005 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de virus
C07K 16/00 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux
C07K 14/33 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de bactéries provenant de Clostridium (G)
A61K 39/215 - Coronaviridae, p. ex. virus de la bronchite infectieuse aviaire
A61P 31/14 - Antiviraux pour le traitement des virus ARN
A61K 47/50 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament
KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (République de Corée)
Inventeur(s)
Kim, Kyungjin
Kim, Kwangrok
Kim, Uk-Il
Bang, Hyung Tae
Lee, Seul Ki
Jeong, Kwan-Young
Kang, Seung Kyu
Jung, Heejung
Rhee, Sang Dal
Jung, Won Hoon
Lee, Jun Mi
Abrégé
Provided is a phthalazinone compound, or a racemate, steroisomer or pharmaceutically acceptable salt thereof; a pharmaceutical composition for the prevention or treatment of Sirt6-associated diseases, including as an active ingredient, a phthalazinone compound, or a racemate, steroisomer or pharmaceutically acceptable salt thereof; and a method for treating Sirt6-associated diseases including administering a phthalazinone compound, or a racemate, steroisomer or pharmaceutically acceptable salt thereof to a subject in need.
C07D 237/32 - Phtalazines avec des atomes d'oxygène liés directement aux atomes de carbone du cycle contenant l'azote
C07D 401/10 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant deux hétérocycles liés par une chaîne carbonée contenant des cycles aromatiques
C07D 405/04 - Composés hétérocycliques contenant à la fois un ou plusieurs hétérocycles comportant des atomes d'oxygène comme uniques hétéro-atomes du cycle et un ou plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle contenant deux hétérocycles liés par une liaison directe de chaînon cyclique à chaînon cyclique
C07D 401/04 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant deux hétérocycles liés par une liaison directe de chaînon cyclique à chaînon cyclique
C07D 403/04 - Composés hétérocycliques contenant plusieurs hétérocycles, comportant des atomes d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant deux hétérocycles liés par une liaison directe de chaînon cyclique à chaînon cyclique
The present invention relates to a method for preparing a pyrrolopyridine derivative compound exhibiting antiviral activity, and a novel intermediate used therein. The preparation method of the present invention enables reaction steps to be reduced through effective process development and a high purity pyrrolopyridine derivative compound to be prepared in a high yield, and thus enables production costs to be remarkably reduced so as to be economical and to be suitable for mass production.
C07D 403/06 - Composés hétérocycliques contenant plusieurs hétérocycles, comportant des atomes d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant deux hétérocycles liés par une chaîne carbonée ne contenant que des atomes de carbone aliphatiques
A61K 31/437 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle condensés en ortho ou en péri avec des systèmes hétérocycliques le système hétérocyclique contenant un cycle à cinq chaînons ayant l'azote comme hétéro-atome du cycle, p. ex. indolizine, bêta-carboline
The present invention relates to a novel oligonucleotide primer used for the synthesis of 5'-capped RNA. The novel oligonucleotide primer for RNA capping provided as chemical formula 1 in the present invention can be usefully utilized in the fields of nucleic acid therapeutic agents or vaccines.
C07H 21/02 - Composés contenant au moins deux unités mononucléotide comportant chacune des groupes phosphate ou polyphosphate distincts liés aux radicaux saccharide des groupes nucléoside, p. ex. acides nucléiques avec le ribosyle comme radical saccharide
C12N 15/113 - Acides nucléiques non codants modulant l'expression des gènes, p. ex. oligonucléotides anti-sens
A61K 31/7088 - Composés ayant au moins trois nucléosides ou nucléotides
68.
GEL COMPOSITION FOR DISINFECTION AND MANUFACTURING METHOD THEREFOR
DONG-A PHARMACEUTICAL CO., LTD. (République de Corée)
Inventeur(s)
Lee, Eunseok
Han, Sangduk
Hyun, Seungmin
Lee, Sungwon
Abrégé
The present invention relates to a highly moisturizing gel composition for disinfection, exhibiting excellent antibacterial activity and stability, and a manufacturing method therefor.
A61K 8/81 - Cosmétiques ou préparations similaires pour la toilette caractérisés par la composition contenant des composés organiques macromoléculaires obtenus par des réactions faisant intervenir uniquement des liaisons insaturées carbone-carbone
A61K 8/84 - Cosmétiques ou préparations similaires pour la toilette caractérisés par la composition contenant des composés organiques macromoléculaires obtenus par des réactions autres que celles faisant intervenir uniquement des liaisons insaturées carbone-carbone
A61Q 17/00 - Préparations protectricesPréparations employées en contact direct avec la peau pour protéger des influences extérieures, p. ex. des rayons du soleil, des rayons X ou d'autres rayons nuisibles, des matériaux corrosifs, des bactéries ou des piqûres d'insectes
A61Q 19/00 - Préparations pour les soins de la peau
01 - Produits chimiques destinés à l'industrie, aux sciences ainsi qu'à l'agriculture
Produits et services
Industrial chemicals; chemical additives for industrial
purposes; reagents for scientific purposes; reagents for
medical research; chemicals for use in biotechnological
manufacturing processes; chemicals for use in
biotechnological product development; biological
preparations for use in biotechnology [other than medical];
chemical preparations for use in the manufacture of
pharmaceuticals; chemicals for the manufacture of vaccines;
chemicals for the manufacture of nucleic acids; chemicals
for the manufacture of mRNA drugs; chemicals for use in the
manufacture of preparations for mRNA therapeutics; chemicals
for the manufacture of mRNA vaccines; excipients for drug
delivery; lipid nanoparticles for drug delivery [chemical
preparations for use in the manufacture of pharmaceuticals];
excipients for mRNA drug delivery; lipid nanoparticles for
mRNA drug delivery [chemical preparations for use in the
manufacture of pharmaceuticals].
The present invention relates to a pyrrolopyridine derivative, a racemate thereof, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, and use thereof. The compound of the present invention has high selectivity and bioactivity against human immunodeficiency virus (HIV), and low toxicity, thus being particularly useful as a therapeutic agent for HIV infection.
A61K 31/437 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle condensés en ortho ou en péri avec des systèmes hétérocycliques le système hétérocyclique contenant un cycle à cinq chaînons ayant l'azote comme hétéro-atome du cycle, p. ex. indolizine, bêta-carboline
A61P 31/18 - Antiviraux pour le traitement des virus ARN du HIV
01 - Produits chimiques destinés à l'industrie, aux sciences ainsi qu'à l'agriculture
Produits et services
(1) Chemical preparations for use in the manufacture of pharmaceuticals; chemicals for the manufacture of vaccines; excipients for drug delivery; lipid nanoparticles for drug delivery [chemical preparations for use in the manufacture of pharmaceuticals]; excipients for mRNA drug delivery; lipid nanoparticles for mRNA drug delivery [chemical preparations for use in the manufacture of pharmaceuticals]
01 - Produits chimiques destinés à l'industrie, aux sciences ainsi qu'à l'agriculture
Produits et services
Industrial chemicals; chemical additives for industrial purposes; reagents for scientific purposes; reagents for medical research; chemicals for use in biotechnological manufacturing processes; chemicals for use in biotechnological product development; biological preparations for use in biotechnology science other than medical use; chemical preparations for use in the manufacture of pharmaceuticals; chemicals for the manufacture of vaccines; chemicals for the manufacture of nucleic acids; chemicals for the manufacture of mRNA drugs; chemicals for use in the manufacture of preparations for mRNA therapeutics; chemicals for the manufacture of mRNA vaccines; excipients for drug delivery for use in the manufacture of pharmaceutical preparations; lipid nanoparticles for drug delivery being chemical preparations for use in the manufacture of pharmaceuticals; excipients for mRNA drug delivery for use in the manufacture of pharmaceutical preparations; lipid nanoparticles for mRNA drug delivery being chemical preparations for use in the manufacture of pharmaceuticals
01 - Produits chimiques destinés à l'industrie, aux sciences ainsi qu'à l'agriculture
Produits et services
Industrial chemicals; chemical additives for industrial
purposes; reagents for scientific purposes; reagents for
medical research; chemicals for use in biotechnological
manufacturing processes; chemicals for use in
biotechnological product development; biological
preparations for use in biotechnology [other than medical];
chemical preparations for use in the manufacture of
pharmaceuticals; chemicals for the manufacture of vaccines;
reagents for the manufacture of nucleic acids; reagents for
the manufacture of mRNA drugs; reagents for use in the
manufacture of preparations for mRNA therapeutics; reagents
for the manufacture of mRNA vaccines; excipients for drug
delivery; lipid nanoparticles for drug delivery; excipients
for mRNA drug delivery; lipid nanoparticles for mRNA drug
delivery.
01 - Produits chimiques destinés à l'industrie, aux sciences ainsi qu'à l'agriculture
Produits et services
Chemicals for use in industry; chemical intermediates for
industrial purposes; reagents for scientific purposes;
reagents for medical research; chemicals for use in
biotechnological manufacturing processes; chemicals for use
in biotechnological product development; biological
preparations for use in biotechnology [other than medical];
chemical preparations for use in the manufacture of
pharmaceuticals; chemicals for the manufacture of vaccines;
reagents for the manufacture of nucleic acids; reagents for
the manufacture of mRNA; reagents for use in the manufacture
of preparations for mRNA therapeutics; reagents for the
manufacture of mRNA vaccines; mRNA capping reagents.
The present invention provides a novel method for preparing high-purity gadobutrol or hydrates thereof. The preparation method of the present invention can have an advantage of simplifying a process by forming a gadolinium complex in-situ without purification of a butrol intermediate and omitting a resin purification process unlike a conventional method for synthesizing gadobutrol. In addition, the preparation method of the present invention can be used to produce high-purity gadobutrol or hydrates thereof at a high yield only through the simple process as above, and thus can be useful in mass production.
The present invention relates to heparin-bile acid oligomer conjugates used in anticancer therapy. Particularly, the present invention provides: a pharmaceutical composition for anticancer or an anticancer adjuvant, containing a compound represented by chemical formula I or a pharmaceutically acceptable salt thereof; and an anticancer combined composition containing the pharmaceutical composition and one or more anticancer agents. A compound represented by chemical formula I or a pharmaceutically acceptable salt thereof of the present invention inhibits cancer-related thrombosis so as to alleviate tumor perfusion, thereby exhibiting excellent anticancer effects when administered alone or in combination with another anticancer agent, and thus can be used as an effective anticancer therapy when administered alone or used in combination with another anticancer therapy.
A61K 47/54 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique
01 - Produits chimiques destinés à l'industrie, aux sciences ainsi qu'à l'agriculture
Produits et services
Chemical additives for industrial purposes; reagents for scientific purposes; reagents for medical research; chemicals for use in biotechnological manufacturing processes; chemicals for use in biotechnological product development; biological preparations for use in biotechnology science other than medical use; chemical preparations for use in the manufacture of pharmaceuticals; chemicals for the manufacture of vaccines; chemicals for the manufacture of nucleic acids; chemicals for the manufacture of mRNA drugs; chemicals for use in the manufacture of preparations for mRNA therapeutics; chemicals for the manufacture of mRNA vaccines; excipients for drug delivery for use in the manufacture of pharmaceutical preparations; lipid nanoparticles for drug delivery being chemical preparations for use in the manufacture of pharmaceuticals; excipients for mRNA drug delivery for use in the manufacture of pharmaceutical preparations; lipid nanoparticles for mRNA drug delivery being chemical preparations for use in the manufacture of pharmaceuticals
01 - Produits chimiques destinés à l'industrie, aux sciences ainsi qu'à l'agriculture
Produits et services
(1) Chemical preparations for use in the manufacture of pharmaceuticals; reagents for the manufacture of nucleic acids; reagents for the manufacture of mRNA drugs; reagents for use in the manufacture of preparations for mRNA therapeutics; reagents for the manufacture of mRNA vaccines; excipients for drug delivery; lipid nanoparticles for drug delivery; excipients for mRNA drug delivery; lipid nanoparticles for mRNA drug delivery
01 - Produits chimiques destinés à l'industrie, aux sciences ainsi qu'à l'agriculture
Produits et services
Chemicals for use in industry; chemical intermediates for industrial purposes; reagents for scientific purposes; reagents for medical research; chemicals for use in biotechnological manufacturing processes; chemicals for use in biotechnological product development; biological preparations for use in biotechnology science other than medical use; chemical preparations for use in the manufacture of pharmaceuticals; chemicals for the manufacture of vaccines; chemical reagents for the manufacture of nucleic acids; chemical reagents for the manufacture of mRNA; chemical reagents for use in the manufacture of preparations for mRNA therapeutics; chemical reagents for the manufacture of mRNA vaccines; mRNA capping reagents for scientific and research use
80.
COMPOSITION, COMPRISING AN ARTEMISIA PRINCEPS LEAF EXTRACT, FOR ALLEVIATION OF SKIN DAMAGE
DONG-A PHARMACEUTICAL CO., LTD. (République de Corée)
Inventeur(s)
Lee, Tae Ho
Sohn, Yong Sung
Baek, Nam Joon
Abrégé
The present invention relates to a composition, comprising an Artemisia princeps leaf extract, for alleviation of skin damage and, more specifically, to a cosmetic composition and a dermatologic agent for external use, a method for alleviating skin damage by using same, and a use thereof for alleviating skin damage, wherein the composition and the agent each comprises (i) an Artemisia princeps leaf extract; and (ii) sodium heparin; (iii) allantoin, and (iv) dexpanthenol as active ingredients.
A61K 8/49 - Cosmétiques ou préparations similaires pour la toilette caractérisés par la composition contenant des composés organiques contenant des composés hétérocycliques
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Nutraceutical preparations mainly based on egg; baby food
made from agricultural products; pharmaceutical preparations
for regulating the immune system; mineral supplements to
foodstuffs; mineral supplements; health food supplements
made principally of minerals; health food supplements made
principally of vitamins; medicated candies; medicated
confectionery; capsules for medicines; food for babies;
dietetic foods adapted for infants; dietary supplements for
infants; mineral drinks (Medicated -); vitamin fortified
beverages for medical purposes; pharmaceuticals;
multivitamins; vitamin enriched bread for therapeutic
purposes.
82.
Nucleoside or nucleotide derivatives, and uses thereof
The present disclosure relates to a novel nucleoside or nucleotide derivative, a racemate thereof, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof; and a pharmaceutical composition for preventing or treating viral infection-associated diseases, containing the same as an active ingredient.
Wholesale store services featuring air deodorizing preparations; wholesale and retail store services featuring toiletry preparations; wholesale store services featuring nutraceuticals for use as a dietary supplement; wholesale store services featuring medicated soap; wholesale store services featuring tissues and wipes impregnated with pharmaceutical lotions and creams; retail store services featuring skin care preparations for medical purposes; wholesale store services featuring skin care preparations for medical purposes; wholesale store services featuring medicinal creams; wholesale store services featuring fragrances for personal use; Promoting the goods and services of others by means of operating an on-line shopping mall with links to the retail web sites of others; business intermediary services relating to mail order by telecommunications, namely, providing business advisory services; wholesale store services featuring cosmetic utensils; advertising services relating to cosmetics; providing consumer product information relating to cosmetics; wholesale store services featuring cosmetics; retail store services featuring cosmetics; marketing research services in the fields of cosmetics, perfumery and beauty products
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Health food supplements based mainly on eggs; protein
dietary supplements; nutritional supplements consisting
primarily of magnesium; food supplements consisting of
minerals; mineral nutritional supplements; dietetic
substances consisting of vitamins, minerals, amino acids and
trace elements; vitamin preparations; nutraceuticals for use
as a dietary supplement; dietary supplement drinks;
nutraceuticals for use as dietary supplements; dietary and
nutritional supplements; vitamin preparations in the nature
of food supplements; nutritional supplements;
pharmaceuticals; nutraceuticals for therapeutic purposes;
nutraceutical preparations for therapeutic or medical
purposes; calcium supplements.
KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (République de Corée)
Inventeur(s)
Kim, Kyungjin
Kim, Kwangrok
Kim, Uk-Il
Bang, Hyung Tae
Lee, Seul Ki
Jeong, Kwan-Young
Kang, Seung Kyu
Jung, Heejung
Lee, Sang Dal
Jung, Won Hoon
Lee, Jun Mi
Abrégé
The present invention relates to: a phthalazinone compound, or a racemate, stereoisomer, or pharmaceutically acceptable salt thereof; a pharmaceutical composition for the prevention or treatment of Sirt6-associated diseases, comprising, as an active ingredient, a phthalazinone compound, or a racemate, stereoisomer, or pharmaceutically acceptable salt thereof; and a method for treating Sirt6-associated diseases comprising administering a phthalazinone compound, or a racemate, stereoisomer, or pharmaceutically acceptable salt thereof to a subject in need of this.
A61P 1/16 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif des troubles de la vésicule biliaire ou du foie, p. ex. protecteurs hépatiques, cholagogues, cholélitholytiques
86.
Pyrrolopyridine derivative, method for producing same, and use thereof
Provided is a novel pyrrolopyridine compound represented by Chemical Formula I, a racemate or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof; and to a method for preparing the same. A compound represented by Chemical Formula I shows high selectivity and antiviral activity against human immunodeficiency virus (HIV), with low toxicity; therefore, it is useful as a therapeutic agent for viral infection, in particular, HIV infection.
DONG-A PHARMACEUTICAL CO., LTD. (République de Corée)
Inventeur(s)
Lee, Tae Ho
Baek, Nam Joon
Kwon, Yong Sam
Cho, Young Woong
Lee, Bong Gyeong
Jiang, Hai Hua
Park, So Mi
Shim, Ka Young
Kim, Yun Hee
Kim, Ju Mi
Kim, Dae Young
Abrégé
Cordyceps militarisCordyceps militarisCordyceps militaris concentrate of the present invention exhibits proven estrogenic activity and reduces weight increase, diet increase, body fat and abdominal fat, which are induced by woman menopause in a woman menopause-induced animal model, and thus has an excellent effect of preventing or reducing woman menopause symptoms and obesity accompanying woman menopause symptoms.
A61K 31/7076 - Composés ayant des radicaux saccharide et des hétérocycles ayant l'azote comme hétéro-atome d'un cycle, p. ex. nucléosides, nucléotides contenant des cycles à six chaînons avec l'azote comme hétéro-atome d'un cycle contenant des pyrimidines condensées ou non-condensées contenant des purines, p. ex. adénosine, acide adénylique
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Health food supplements based mainly on eggs; protein dietary supplements; nutritional supplements consisting primarily of magnesium; food supplements consisting of minerals; mineral nutritional supplements; dietary supplements consisting of vitamins, minerals, amino acids and trace elements; vitamin preparations; nutraceuticals for use as a dietary supplement; dietary supplement drinks; nutraceuticals for use as dietary supplements; dietary and nutritional supplements; vitamin preparations in the nature of food supplements; nutritional supplements; pharmaceuticals for supporting liver health, prostate health, skin health, joint health, bones and teeth health, eye health and promoting digestion and improving blood flow and boosting immunity; nutraceuticals for therapeutic purposes for supporting liver health, prostate health, skin health, joint health, bones and teeth health, eye health and promoting digestion and improving blood flow and boosting immunity; nutraceutical preparations for therapeutic or medical purposes for supporting liver health, prostate health, skin health, joint health, bones and teeth health, eye health and promoting digestion and improving blood flow and boosting immunity; calcium supplements
89.
INTERMEDIATE FOR PRODUCING PHENAZINE DERIVATIVE, AND METHOD FOR PRODUCING SAME
22 with a polar aprotic solvent having a boiling point higher than the reaction temperature, and CPDA prepared by reacting 4-CA and F-NO2 with a sulfur compound having an oxidation number of -2; clofazimine produced using the prepared CPNA or CPDA; and a method for producing same. The present invention can maximize production efficiency through process simplification and process stability improvement during the preparation of CPNA. Also, the present invention can produce CPDA at high yield and high purity by using a sulfur compound as a reducing agent. In addition, compared to conventional processes for removing by-products through work-up processes, the present invention can easily remove by-products by using only purified water-washing, thus being advantageous for commercialization, and can achieve an eco-friendly process by minimizing solvents.
C07C 209/68 - Préparation de composés contenant des groupes amino liés à un squelette carboné à partir d'amines, par des réactions n'impliquant pas de groupes amino, p. ex. réduction d'amines non saturées, aromatisation ou substitution du squelette carboné
C07C 211/52 - Composés contenant des groupes amino liés à un squelette carboné ayant des groupes amino liés à des atomes de carbone de cycles aromatiques à six chaînons du squelette carboné ayant des groupes amino liés à un seul cycle aromatique à six chaînons le squelette carboné étant substitué de plus par des atomes d'halogène ou par des groupes nitro ou nitroso
C07C 209/36 - Préparation de composés contenant des groupes amino liés à un squelette carboné par réduction de liaisons azote-oxygène ou azote-azote par réduction de groupes nitro par réduction de groupes nitro liés à des atomes de carbone de cycles aromatiques à six chaînons
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Pharmaceutical agents affecting metabolism; vitamin preparations; pharmaceutical preparations for the treatment of cardiovascular disorders; nutritional supplements, namely, tonics and tonic alternatives for medical purposes; pharmaceutical preparations for the treatment of tumor; pharmaceutical preparations acting on the central nervous system; pharmaceutical preparations for treating respiratory diseases
The present invention provides a novel method for producing gadobutrol of high purity or a hydrate thereof. Unlike the conventional method for synthesizing gadobutrol, the production method of the present invention can simplify the process by forming a gadolinium complex in-situ without purification of butrol intermediates, and can eliminate the resin purification process. In addition, the production method of the present invention can produce gadobutrol of high purity or a hydrate thereof in a high yield merely by a simple process as described above, and thus can be beneficially used for high-throughput production.
C07D 257/02 - Composés hétérocycliques contenant des cycles comportant quatre atomes d'azote comme uniques hétéro-atomes du cycle non condensés avec d'autres cycles
DONG-A PHARMACEUTICAL CO., LTD. (République de Corée)
Inventeur(s)
Jun, Joon Ho
Han, Sang Dug
Kim, Hee Eun
Abrégé
The present invention relates to a suspension containing ibuprofen and, more specifically, to: a pharmaceutical suspension composition allowing the administration of an accurate amount of an active substance even though a patient does not shake the pharmaceutical suspension composition upon taking; a pharmaceutical agent in which a packaging container including an inner layer of aluminum, glass, or a polymer is charged with the pharmaceutical suspension composition; and a manufacturing method therefor.
A61K 47/26 - Hydrates de carbone, p. ex. polyols ou sucres alcoolisés, sucres aminés, acides nucléiques, mono-, di- ou oligosaccharidesLeurs dérivés, p. ex. polysorbates, esters d’acide gras de sorbitan ou glycyrrhizine
A61K 31/192 - Acides carboxyliques, p. ex. acide valproïque ayant des groupes aromatiques, p. ex. sulindac, acides 2-aryl-propioniques, acide éthacrynique
A61K 47/36 - PolysaccharidesLeurs dérivés, p. ex. gommes, amidon, alginate, dextrine, acide hyaluronique, chitosane, inuline, agar-agar ou pectine
A61J 1/14 - Récipients spécialement adaptés à des fins médicales ou pharmaceutiques DétailsAccessoires à cet effet
93.
Heteroaryl compound, enantiomer, diastereomer or pharmaceutically acceptable salt thereof, and antiviral composition containing same as active ingredient
The present invention relates to a novel heteroaryl compound, an enantiomer, a diastereomer or a pharmaceutically acceptable salt thereof, and an antiviral composition comprising the same as an active ingredient. The novel compounds represented by formula (I) or formula (II) according to the present invention are remarkably superior in antiviral activity against an influenza virus, and furthermore, have low cytotoxicity and thus low adverse effects on a human body. Therefore, a pharmaceutical composition containing the same as an active ingredient can be effectively used for the prevention or treatment of diseases caused by an influenza virus infection.
C07D 413/06 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes d'azote et d'oxygène comme uniques hétéro-atomes du cycle contenant deux hétérocycles liés par une chaîne carbonée contenant uniquement des atomes de carbone aliphatiques
C07D 271/113 - Oxadiazoles-1, 3, 4Oxadiazoles-1, 3, 4 hydrogénés avec des atomes d'oxygène, de soufre ou d'azote, liés directement aux atomes de carbone du cycle, les atomes d'azote ne faisant pas partie d'un radical nitro
C07D 405/06 - Composés hétérocycliques contenant à la fois un ou plusieurs hétérocycles comportant des atomes d'oxygène comme uniques hétéro-atomes du cycle et un ou plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle contenant deux hétérocycles liés par une chaîne carbonée contenant uniquement des atomes de carbone aliphatiques
The present invention provides ergostenol glycoside derivatives, method for preventing, treating, or alleviating dermatitis using the same. The present invention also provides a method for preparing the ergostenol and glycoside derivatives thereof. The ergostenol and the glycoside derivatives thereof according to the present invention suppress the production of chemokines increasing according to the skin inflammation stimulation and inhibit the activity of transcriptional factors controlling the expression of various inflammation mediators in the prevention and treatment of dermatitis.
C07J 17/00 - Stéroïdes normaux contenant du carbone, de l'hydrogène, un halogène, ou de l'oxygène, ayant un hétérocycle contenant de l'oxygène non condensé avec le squelette du cyclopenta[a]hydrophénanthrène
C07H 15/24 - Systèmes cycliques condensés comportant au moins trois cycles
A61P 17/00 - Médicaments pour le traitement des troubles dermatologiques
A61K 31/7034 - Composés ayant des radicaux saccharide liés à des composés non-saccharide par des liaisons glycosidiques liés à un composé carbocyclique, p. ex. phloridzine
DONG-A PHARMACEUTICAL CO., LTD. (République de Corée)
Inventeur(s)
Jun, Joon Ho
Park, Hyoung Geun
Baek, Nam Joon
Yu, Jae Young
Cho, Sung Mo
Abrégé
The objective of the present invention is to provide a composition for liver protection containing turmeric extract and rice germ soybean fermented extract as active ingredients. Specifically, the mixture of turmeric extract and rice germ soybean fermented extract has effects such as liver damage protection, fatty liver suppression, and hangover relief which are far superior to each of the substances thereof.
C07C 211/27 - Composés contenant des groupes amino liés à un squelette carboné ayant des groupes amino liés à des atomes de carbone acycliques d'un squelette carboné non saturé contenant au moins un cycle aromatique à six chaînons ayant des groupes amino reliés au cycle aromatique à six chaînons par l'intermédiaire de chaînes carbonées saturées
C07C 209/22 - Préparation de composés contenant des groupes amino liés à un squelette carboné par substitution de groupes fonctionnels par des groupes amino par substitution d'autres groupes fonctionnels
C07C 269/06 - Préparation de dérivés d'acide carbamique, c.-à-d. de composés contenant l'un des groupes l'atome d'azote ne faisant pas partie de groupes nitro ou nitroso par des réactions n'impliquant pas la formation de groupes carbamate
C07C 271/20 - Esters des acides carbamiques ayant des atomes d'oxygène de groupes carbamate liés à des atomes de carbone acycliques avec les atomes d'azote des groupes carbamate liés à des atomes d'hydrogène ou à des atomes de carbone acycliques à des atomes de carbone de radicaux hydrocarbonés substitués par des atomes d'azote ne faisant pas partie de groupes nitro ou nitroso
C07C 217/62 - Composés contenant des groupes amino et hydroxy éthérifiés liés au même squelette carboné ayant des groupes hydroxy éthérifiés liés à des atomes de carbone d'au moins un cycle aromatique à six chaînons et des groupes amino liés à des atomes de carbone acycliques ou à des atomes de carbone de cycles autres que des cycles aromatiques à six chaînons du même squelette carboné avec des groupes amino reliés au cycle aromatique à six chaînons, ou au système cyclique condensé contenant ce cycle, par l'intermédiaire de chaînes carbonées qui ne sont pas substituées de plus par des atomes d'oxygène liés par des liaisons simples reliés par l'intermédiaire de chaînes carbonées ayant au moins trois atomes de carbone entre les groupes amino et le cycle aromatique à six chaînons ou le système cyclique condensé contenant ce cycle
97.
FILM-FORMING PHARMACEUTICAL COMPOSITION CONTAINING NONSTEROIDAL ANTI-INFLAMMATORY ANALGESIC ACTIVE INGREDIENT
DONG-A PHARMACEUTICAL CO., LTD. (République de Corée)
Inventeur(s)
Jun, Joon Ho
Han, Sang Dug
Kang, Min Hyung
Abrégé
The present invention relates to: a pharmaceutical composition, which contains a nonsteroidal anti-inflammatory analgesic active ingredient (NSAID), is convenient to use because of the formation of a film during application to an affected part, allows absorption to be maximized, and has low skin irritation; and a preparation method therefor. A pharmaceutical composition according to the present invention allows a film to be rapidly formed during application to an affected part so as not to be sticky and get on clothes and the like, unlike a conventional preparation for external use, and thus is convenient to use. In addition, the composition can be easily applied to places, such as finger joints, the knees, and the elbows, where attaching adhesives such as plaster is difficult. Moreover, treatment efficiency can be maximized by remarkably increasing drug absorption from the formulation to the affected part and has low skin irritation, thereby enabling abnormal skin symptoms such as rubefaction to be minimized even when applied to the skin for a long time. Therefore, the present invention can provide a pharmaceutical composition which is effective and convenient to use by patients who expect analgesic and anti-inflammatory analgesic effects with respect to osteoarthritis, periarthritis of shoulder, muscular pain and peritenonitis symptoms.
A61K 31/192 - Acides carboxyliques, p. ex. acide valproïque ayant des groupes aromatiques, p. ex. sulindac, acides 2-aryl-propioniques, acide éthacrynique
A61K 31/196 - Acides carboxyliques, p. ex. acide valproïque ayant un groupe amino le groupe amino étant lié directement à un cycle, p. ex. acide anthranilique, acide méfénamique, diclofénac, chlorambucil
A61K 31/54 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec au moins un azote et au moins un soufre comme hétéro-atomes d'un cycle, p. ex. sulthiame
The present invention relates to: novel nucleoside or nucleotide derivatives, racemates thereof, stereoisomers thereof, or pharmaceutically acceptable salts thereof; and a pharmaceutical composition for preventing or treating viral infection-associated diseases, containing the same as an active ingredient.
03 - Produits cosmétiques et préparations de toilette; préparations pour blanchir, nettoyer, polir et abraser.
Produits et services
Non-medicated toiletry preparations; cuticle removing preparations; cosmetics; skin lotion for men; anti-aging cosmetics; cosmetics and make-up; cosmetic preparations for the hair and scalp; body and beauty care cosmetics; beauty care cosmetics; non-medicated preparations for the care of skin, hair and scalp; sun block; skin whitening preparations; essential oils for use in the manufacture of scented products; non-medicated soaps for household use; shampoos; breath freshening preparations for personal hygiene; shampoos for animals
100.
N-DEOXYRIBOSYL TRANSFERASE MUTANT AND NUCLEOSIDE PREPARING METHOD USING SAME
The present invention relates to an N-deoxyribosyl transferase mutant, a polynucleotide coding for the mutant, a vector carrying the polynucleotide, a microorganism containing the polynucleotide, and a method for preparing a nucleoside, using the same vector and microorganism.
C12N 15/70 - Vecteurs ou systèmes d'expression spécialement adaptés à E. coli
C12P 19/18 - Préparation de composés contenant des radicaux saccharide préparés par action d'une transférase glycosylique, p. ex. alpha-, bêta- ou gamma-cyclodextrines
